Tobira Therapeutics raises $31m in its series B round.
US-based biopharmaceutical company Tobira Therapeutics has raised $31m in its series B round led by Denmark-based medical foundation Novo.
Venture capital firm Domain Associates, which incubated the company in 2006 to develop treatments for HIV disease, also invested in the B round consortium alongside peers Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
